Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest LaboratoriesNSE:QUESTLAB -1.93%45 Capex-to-Operating-Income is 0.08 as of Mar. 2026, which is 74% below its 10-year median of 0.31. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 45/100. The stock has 5 warning signs investors should review. Among 499 Drug Manufacturers companies, Quest Laboratories ranks better than 59.72% on this metric.
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Quest Laboratories Capex-to-Operating-Income Related Terms
Quest Laboratories Capex-to-Operating-Income Historical Data
* Premium members only.
The historical data trend for Quest Laboratories's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:QUESTLAB vs LLY, JNJ, ABBV: Capex-to-Operating-Income Comparison
For the Drug Manufacturers - General subindustry, Quest Laboratories's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Laboratories Capex-to-Operating-Income vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Quest Laboratories's Capex-to-Operating-Income falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Income of 0.08 mean?
Quest Laboratories (NSE:QUESTLAB) has a Capex-to-Operating-Income of 0.08 as of Mar. 2026. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Quest Laboratories and its competitors. This is 74% below median its historical median of 0.31. Over the past decade, Quest Laboratories' Capex-to-Operating-Income has ranged from 0.06 to 1.14. According to the industry distribution chart, Quest Laboratories ranks #201 out of 499 companies in the Drug Manufacturers industry, placing it in the top 40.3%.
Is Quest Laboratories' Capex-to-Operating-Income too high?
Quest Laboratories' current Capex-to-Operating-Income of 0.08 is 74% below median its 10-year median of 0.31. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 1.14. The Drug Manufacturers industry median Capex-to-Operating-Income is 0.39. Quest Laboratories' value of 0.08 is 79.5% below this industry median. Based on the distribution chart, Quest Laboratories ranks #201 out of 499 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Quest Laboratories has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' Capex-to-Operating-Income compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #201 out of 499 companies for Capex-to-Operating-Income. This puts Quest Laboratories in the upper half of its industry. The industry median Capex-to-Operating-Income is 0.39. Quest Laboratories' value of 0.08 is 79.5% below this benchmark. Historically, Quest Laboratories' own Capex-to-Operating-Income has ranged from 0.06 to 1.14 over the past decade. While the company's 10-year median is 0.31 vs. the industry median of 0.39, Quest Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Income for a Drug Manufacturers company?
The median Capex-to-Operating-Income among Drug Manufacturers companies is 0.39, based on 499 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Income significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Laboratories's current Capex-to-Operating-Income of 0.08 is 79.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Income mean?
A high Capex-to-Operating-Income can signal that a stock is expensive relative to its fundamentals. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Quest Laboratories and its competitors. For the Drug Manufacturers industry, the median Capex-to-Operating-Income is 0.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current Capex-to-Operating-Income is 0.08, which is 74% below median its own 10-year median of 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current Capex-to-Operating-Income of 0.08. The current Capex-to-Operating-Income is 0.08, which is 74% below median its 10-year median of 0.31 and 79.5% below the Drug Manufacturers industry median of 0.39. Quest Laboratories' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Income calculated?
Capex-to-Operating-Income is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current Capex-to-Operating-Income is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
45GF Score
Get the complete analysis for NSE:QUESTLAB
Capex-to-Operating-Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QUESTLAB has been successfully added to your 
